![conference banner](/images/conference-banner.jpeg)
Abstract
West Nile virus (WNV) is a mosquito-borne disease that emerged in North America. In 2002 it caused the largest arboviral meningoencephalitis outbreak ever recorded in the US and Canada. The key enzyme responsible for the replication of the virus is the RNA-dependent RNA polymerase (RdRp) enzyme represented by nonstructural protein NS5 in WNV To understand the structural basis and enzymatic activity of WNV RdRp as well as potential drug susceptibility, we have built a homology model of WNV NS5 RdRp based on a combination of motif search, fold recognition and sequence alignments orchestrated by 3D-jury system. We have located conserved sequence motifs shared by all RdRps and described the potential functional role of these motifs and specific residues in the polymerization and in the recognition of potential inhibitors. Virtual docking of several substrates and inhibitors in our WNV RdRp model shows that a non-nucleoside inhibitor such as 2-methyl-ribofuranosyl-guanosine triphosphate has a higher binding energy indicated by a low free energy obtained upon binding. These results provide a preliminary basis for the development of anti-WNV agents based on RNA dependant RNA polymerase inhibition.
Keywords: West nile virus, RNA dependent RNA polymerase, molecular modeling, inhibitors
Medicinal Chemistry
Title: Structure Function Analysis of West Nile Virus RNA Dependent RNA Polymerase: Molecular Model and Implications for Drug Design
Volume: 3 Issue: 5
Author(s): Arezki Azzi and Sheng-Xiang Lin
Affiliation:
Keywords: West nile virus, RNA dependent RNA polymerase, molecular modeling, inhibitors
Abstract: West Nile virus (WNV) is a mosquito-borne disease that emerged in North America. In 2002 it caused the largest arboviral meningoencephalitis outbreak ever recorded in the US and Canada. The key enzyme responsible for the replication of the virus is the RNA-dependent RNA polymerase (RdRp) enzyme represented by nonstructural protein NS5 in WNV To understand the structural basis and enzymatic activity of WNV RdRp as well as potential drug susceptibility, we have built a homology model of WNV NS5 RdRp based on a combination of motif search, fold recognition and sequence alignments orchestrated by 3D-jury system. We have located conserved sequence motifs shared by all RdRps and described the potential functional role of these motifs and specific residues in the polymerization and in the recognition of potential inhibitors. Virtual docking of several substrates and inhibitors in our WNV RdRp model shows that a non-nucleoside inhibitor such as 2-methyl-ribofuranosyl-guanosine triphosphate has a higher binding energy indicated by a low free energy obtained upon binding. These results provide a preliminary basis for the development of anti-WNV agents based on RNA dependant RNA polymerase inhibition.
Export Options
About this article
Cite this article as:
Azzi Arezki and Lin Sheng-Xiang, Structure Function Analysis of West Nile Virus RNA Dependent RNA Polymerase: Molecular Model and Implications for Drug Design, Medicinal Chemistry 2007; 3 (5) . https://dx.doi.org/10.2174/157340607781745438
DOI https://dx.doi.org/10.2174/157340607781745438 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapy for Alzheimers Disease: Potential Problems and Possible Solutions
Current Immunology Reviews (Discontinued) Therapeutic Perspectives in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Targeted Hydrolysis of Beta-Amyloid with Engineered Antibody Fragments
Current Alzheimer Research How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice
Current Alzheimer Research Herpetic (Non-Cytomegalovirus) Retinal Infections in Patients with the Acquired Immunodeficiency Syndrome
Current HIV Research Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS
Current Pharmaceutical Design HTLV-1 Associated Neurological Disorders
Current Topics in Medicinal Chemistry Evaluation of B Lymphocyte Deficiencies
Cardiovascular & Hematological Disorders-Drug Targets Anti-Alzheimer Therapeutic Drugs Targeting γ-Secretase
Current Topics in Medicinal Chemistry Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research
Current Medicinal Chemistry APP Transgenic Mouse Models and their Use in Drug Discovery to Evaluate Amyloid-β Lowering Therapeutics
CNS & Neurological Disorders - Drug Targets Copper, An Ancient Remedy Returning to Fight Microbial, Fungal and Viral Infections
Current Chemical Biology Anti-Viral Agents in Neurodegenerative Disorders: New Paradigm for Targeting Alzheimer’s Disease
Recent Patents on Anti-Infective Drug Discovery Currently Used Biologic Agents in the Management of Behcet’s Syndrome
Current Medicinal Chemistry Quantitative and Mechanistic Studies of Aβ Immunotherapy
CNS & Neurological Disorders - Drug Targets An Inducible Expression System for Recombinant Sca Proteins with an Autotransporter Domain from <i>Orientia Tsutsugamushi in Escherichia coli</i>
Protein & Peptide Letters On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued)